Sequencing Data for a Delta-Omicron Recombinant in an Immunosuppressed Transplant Recipient Treated with Monoclonal Antibody Sotrovimab
- A Delta-Omicron recombinant of the SARS-CoV-2 virus was sequenced and isolated from an immunosuppressed and unvaccinated male kidney transplant patient who received Sotrovimab for treatment of COVID-19. Further clinical details and medical history of the patient are described in the associated publication. Sotrovimab is a therapeutic monoclonal antibody (mAb) used to treat infections by the BA.1 Omicron lineage. It was observed that the Delta-Omicron recombinant found in this patient was resistant to neutralization by Sotrovimab. Genomic analysis of the SARS-CoV-2-positive nasopharyngeal swab specimen revealed an unusual SARS-CoV-2 sequence with outlier Omicron BA.1 placement in a global phylogenetic tree and high number of mutations.